Scientific Posters
Phase 1 Pharmacokinetic (PK) Assessment of ATI-1123, a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation, in Patients with Advanced Solid Malignancies
ATI-1123, a novel nanoparticle docetaxel liposomal formulation, is being investigated in patients (pts) with advanced solid malignancies. ATI-1123 is expected to reduce hypersensitivity reactions, have…
Toxicokinetics and Immunogenicity of CBX129801, a Pegylated C-Peptide Drug for Type 1 Diabetes Replacement Therapy, in Sprague Dawley Rats
To assess toxicokinetics (TK) and immunogenicity of CBX129801 in rats after subcutaneous (SC) injections for 4 weeks (5 doses) with 4-week recovery period.
Toxicokinetics of ETI-385 and its Components ETI-382 and ETI-383, a Serotonin 5-HT1A Receptor Agonist for Treatment of Nausea and Vomiting, Following Subcutaneous Injection of ETI-385 to CD-1 Mice and Beagle Dogs
To assess the toxicokinetics (TK) of ETI-382 and ETI-383 in CD-1 mice and Beagle dogs following subcutaneous injection of ETI-385. ETI-385, an 8-to-1 fixed ratio…
Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Neuropathy, in Rats and Monkeys After Subcutaneous Injections
To assess the toxicokinetics (TK) of CBX129801 in rats and monkeys following once weekly subcutaneous injection for 5 doses
Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, Following Subcutaneous Injection of CBX129801 in Monkeys in a 9-Month Study with a 7-Week Recovery Period
To assess the toxicokinetics (TK) of CBX129801 in Sprague Dawley Rats following once weekly subcutaneous injection for 26 doses.
Pharmacokinetics of AC220 and its Active Metabolite AC886, a FLT-3 Inhibitor, Following Sequential Oral Dose Escalation to Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
AC220, a FLT-3 inhibitor, is being investigated for the treatment of Acute Myeloid Leukemia (AML). The objective of this study was to investigate the safety,…
Effect of Food on the Pharmacokinetics of Ulifloxacin, a Fluoroquinolone for Bacterial Gastroenteritis Treatment, in Healthy Subjects After Oral Dosing of the Prodrug Prulifloxacin
To investigate the effect of food on the pharmacokinetics (PK) of ulifloxacin in healthy individuals following a single oral dosing of the prodrug prulifloxacin at…
Comparison of Encapsulated and Non-encapsulated Doxorubicin Pharmacokinetics Following Single Intravenous Administration of ATI-0918, an Encapsulated Liposomal Formulation, and DOXIL® in Female Rats
To compare the pharmacokinetics (PK) of encapsulated and non encapsulated doxorubicin following a 6 mg/kg IV bolus dose of ATI-0918 or DOXIL® (CAELYX®) in female…
Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-Peptide in Patients with Type 1 Diabetes Mellitus
To assess the pharmacokinetics (PK) of CBX129801, a long-acting synthetic C-peptide, following subcutaneous (SC) injection in patients with type 1 diabetes mellitus (T1DM).
Pharmacokinetic Bioequivalence of ATI-0918 and DOXIL®/CAELYX® in Patients with Ovarian Cancer
To assess the pharmacokinetic (PK) bioequivalence of ATI-0918 (test product) and DOXIL®/CAELYX® (reference product).